论文部分内容阅读
目的观察阿托伐他汀对降低心肌梗死患者心血管风险的临床效果。方法选取医院接受治疗的心肌梗死患者80例作为研究对象,随机分为对照组和观察组,每组40例。对照组采用辛伐他汀进行治疗,观察组采用阿托伐他汀进行治疗,观察2组患者在治疗后心血管事件的发生率和总胆固醇、三酰甘油水平。结果治疗后,观察组心血管事件发生率为7.50%,低于对照组的27.50%(P<0.05)。治疗前,2组总胆固醇、三酰甘油水平比较差异均无统计学意义(P>0.05);治疗后,观察组总胆固醇、三酰甘油水平均低于对照组,差异有统计学意义(P<0.05)。结论阿托伐他汀能有效降低心肌梗死患者心血管事件发生率、总胆固醇含量和三酰甘油的含量,值得推广应用。
Objective To observe the clinical effect of atorvastatin on reducing cardiovascular risk in patients with myocardial infarction. Methods Totally 80 patients with myocardial infarction treated in our hospital were selected as the research object and randomly divided into control group and observation group, 40 cases in each group. The control group was treated with simvastatin, and the observation group was treated with atorvastatin. The incidence of cardiovascular events and total cholesterol and triglyceride levels after treatment in the two groups were observed. Results After treatment, the incidence of cardiovascular events in the observation group was 7.50%, which was lower than that in the control group (27.50%, P <0.05). Before treatment, there were no significant differences in total cholesterol and triglyceride between the two groups (P> 0.05). After treatment, the levels of total cholesterol and triglyceride in the observation group were lower than those in the control group (P <0.05). Conclusions Atorvastatin can effectively reduce the incidence of cardiovascular events, total cholesterol and triglyceride content in patients with myocardial infarction, which is worth popularizing.